XML 43 R52.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaboration and License Agreements - Additional Information (Detail) (USD $)
 12 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2011
Sep. 30, 2013
Dec. 31, 2012
Sep. 30, 2013
Servier [Member]
Dec. 31, 2012
Servier [Member]
Dec. 31, 2011
Servier [Member]
Sep. 30, 2013
Servier [Member]
Second Right to Develop Collaboration [Member]
Dec. 31, 2012
Servier [Member]
Second Right to Develop Collaboration [Member]
Sep. 30, 2013
Gilead [Member]
Molecule
Sep. 30, 2013
Gilead [Member]
Minimum [Member]
Sep. 30, 2013
Gilead [Member]
Maximum [Member]
Sep. 30, 2013
Gilead [Member]
Expired Option Agreement [Member]
Molecule
Sep. 30, 2013
Gilead [Member]
License Agreement Terms [Member]
Molecule
Sep. 30, 2013
Gilead [Member]
Option Agreement [Member]
Program
Sep. 30, 2013
Boehringer [Member]
Molecule
Payments
Dec. 31, 2012
Boehringer [Member]
Dec. 31, 2011
Boehringer [Member]
Jan. 31, 2011
Boehringer [Member]
Series D-2 Convertible Preferred Stock [Member]
Oct. 31, 2010
Pfizer [Member]
Molecule
Sep. 30, 2013
Pfizer [Member]
Program
Dec. 31, 2012
Pfizer [Member]
Dec. 31, 2011
Pfizer [Member]
Sep. 30, 2013
Green Cross [Member]
Dec. 31, 2012
Green Cross [Member]
Dec. 31, 2011
Green Cross [Member]
Oct. 28, 2010
Eli Lilly [Member]
May 31, 2010
Eli Lilly [Member]
May 31, 2008
Eli Lilly [Member]
Sep. 30, 2013
Eli Lilly [Member]
Dec. 31, 2012
Eli Lilly [Member]
Dec. 31, 2011
Eli Lilly [Member]
License And Collaboration Agreements [Line Items]                                                              
Collaboration agreement date       November 2011     September 2012   January 2013           October 2010       October 2010       June 2010           October 2007    
Non-refundable upfront payment       $ 20,000,000     $ 20,000,000   $ 7,500,000           $ 15,000,000       $ 5,000,000 $ 5,000,000     $ 1,000,000           $ 41,000,000    
Additional license grant fees       30,000,000     65,000,000   7,500,000                                            
Clinical milestone payments       47,000,000     98,000,000               41,000,000                                
Regulatory milestone payments       140,000,000     300,000,000               89,000,000                                
Sales milestone payments       208,000,000     630,000,000               83,000,000         195,000,000                      
Expected period of development       27 months     29 months   21 months                                            
Recognized revenue under agreement       18,900,000 9,100,000 900,000 6,500,000 2,000,000 5,900,000           6,900,000 11,700,000 8,900,000     3,200,000 5,500,000 5,200,000 75,000 100,000 100,000       673,927 31,200,000 30,900,000
Milestone payment       10,000,000                       2,000,000         500,000           5,000,000 50,000,000      
Deferred revenue       3,100,000 10,000,000   11,600,000 18,000,000             10,300,000 14,000,000             675,000 750,000              
Deferred revenue included in current liabilities 31,652,533 21,298,318 24,123,176   9,100,000   8,600,000 8,600,000 4,400,000           5,000,000 5,000,000       58,000 1,300,000   100,000 100,000              
Deferred revenue included in long-term liabilities 23,237,075 8,812,342 19,956,343   900,000   3,000,000 9,400,000             5,300,000 9,000,000             575,000 650,000              
Clinical milestone payments under agreement             5,000,000     20,000,000 25,000,000                 17,000,000     4,500,000                
Commercialization of molecules                 4     1 1 2 10       2                        
Additional clinical, regulatory and sales milestone payments                   240,000,000 250,000,000                                        
Receivables 3,397,869 2,281,282 2,046,219           1,100,000           246,375 355,568 146,150     501,794 896,285 936,010             244,542 558,516 351,357
Number of annual maintenance payments received                             2                                
Received including upfront, annual maintenance and milestone payment                             39,000,000                                
Preferred Stock purchased $ 12,014,815                                 $ 10,000,000                          
Research obligation completion date                             2015-09         2014-01                      
Period of agreement                                     3 years                        
DART program                                       1                      
Term of the agreement                                             2020-06                
Review of clinical data                                                   1 year